Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Swiss Exchange  -  11:31:49 2023-03-31 am EDT
83.76 CHF   +0.49%
03/31Novartis Says European Medicines Agency Committee Backs Approval of Heart Failure Drug for Pediatric Patients
MT
03/31Novartis' Entresto For Pediatric Heart Failure Gets EU Medicines Agency Panel's Backing
MT
03/31Novartis Entresto receives positive CHMP opinion for pediatric heart failure
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis flags faster sales and profit growth for 2015

01/27/2015 | 09:00am EDT

ZURICH (Reuters) - Swiss drugmaker Novartis (>> Novartis AG) said sales and profits would rise at a faster pace this year as recent drug successes and its portfolio overhaul help it weather competition from cheaper generic medicines.

ZURICH (Reuters) - Swiss drugmaker Novartis (>> Novartis AG) said sales and profits would rise at a faster pace this year as recent drug successes and its portfolio overhaul help it weather competition from cheaper generic medicines.

Stripping out the impact of currency fluctuations, the Basel-based firm said it expected mid-single digit sales growth in 2015 while core operating income would increase at a high-single digit rate.

Still, a surge in the Swiss franc following the Swiss central bank's (SNB) decision to scrap its cap on the currency's value may complicate Novartis' efforts to improve margins.

Chief Executive Joe Jimenez said he would review Swiss costs following the franc rise, but would continue to invest in the country, reiterating comments made to Reuters in Davos last week.

He said the franc's surge would not derail efforts to increase margins since the company would take a hard look at procurement and other services it has in Switzerland.

Novartis, which generates just 2 percent of sales but has about 13 percent of its costs in Switzerland, said it expected the stronger franc to knock about 12 percentage points off core operating income this year and 7 percentage points off sales.

To eke out further savings, Novartis has consolidated some back-office functions, which are spread across all divisions and account for around $5 billion (3.3 billion pounds) in expenses, into one shared service organisation.

Shares in Novartis, which slumped as much as 16 percent on the day the SNB scrapped the cap, gained 1.6 percent by 1350 GMT, outperforming a flat European healthcare sector <.SXDP>.

Novartis unveiled a series of deals last year which will see it focus on a smaller number of higher-margin businesses once it concludes a $20 billion asset swap with GlaxoSmithKline (>> GlaxoSmithKline plc) in the first half.

The company hopes the restructuring, as well as the recent approval of its new psoriasis drug Cosentyx which could bring in annual sales of more than $1 billion, will help it buffer cheaper copycat competition to blood pressure medicines Diovan and Exforge.

The anticipated launch of heart failure treatment LCZ696 should also generate multi-billion-dollar revenues. Analysts expect the drug to gain approval in the United States by the middle of this year.

Net sales fell 2 percent in the fourth quarter to $14.63 billion, slightly ahead of the average forecast for $14.6 billion in a Reuters poll. Core net income rose 1 percent to $2.9 billion in line with forecasts.

The company said it would raise its dividend to 2.60 Swiss francs per share for 2014 from 2.45 francs last year. This was below the average forecast for 2.67 francs in a Reuters poll.

(Additional reporting by Ben Hirschler; editing by Jason Neely and David Clarke)

By Caroline Copley

Stocks treated in this article : Novartis AG, GlaxoSmithKline plc

ę Reuters 2015
Stocks mentioned in the article
ChangeLast1st jan.
EURO / SWISS FRANC (EUR/CHF) -0.42% 0.99169 Delayed Quote.0.69%
GSK PLC 0.63% 1429 Delayed Quote.-0.60%
NOVARTIS AG 0.49% 83.76 Delayed Quote.0.20%
All news about NOVARTIS AG
03/31Novartis Says European Medicines Agency Committee Backs Approval of Heart Failure Drug ..
MT
03/31Novartis' Entresto For Pediatric Heart Failure Gets EU Medicines Agency Panel's Backing
MT
03/31Novartis Entresto receives positive CHMP opinion for pediatric heart failure
GL
03/30India exempts import tax on pricey rare disease medicines
RE
03/28Bicycle Therapeutics, Novartis Enter Drug Discovery Collaboration
MT
03/28NOVARTIS AG : UBS sticks Neutral
MD
03/28Oddo BHF Lifts Price Target on Novartis, Maintains Neutral Recommendation
MT
03/28NOVARTIS AG : Deutsche Bank Upgrades to Neutral
MD
03/27Health Care Lags Market as Novartis Rises -- Health Care Roundup
DJ
03/27Global markets live: First Citizens, Adidas, Apple, Standard Charter..
MS
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2023 52 410 M - -
Net income 2023 9 540 M - -
Net Debt 2023 9 547 M - -
P/E ratio 2023 19,9x
Yield 2023 3,81%
Capitalization 209 B 209 B -
EV / Sales 2023 4,17x
EV / Sales 2024 3,97x
Nbr of Employees 101 703
Free-Float 83,6%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 91,78 $
Average target price 99,57 $
Spread / Average Target 8,48%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG0.20%209 026
JOHNSON & JOHNSON-13.14%405 107
NOVO NORDISK A/S15.76%356 186
ELI LILLY AND COMPANY-6.13%309 730
ABBVIE INC.-1.39%281 151
MERCK & CO., INC.-4.11%270 081
1 MarketScreener is worth more than 1000 Influencers!
100% Free Registration
fermer